147403-03-0 | Azilsartan

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$6.00	$4.00
50mg	98%	in stock	$7.00	$5.00
100mg	98%	in stock	$9.00	$6.00
250mg	98%	in stock	$13.00	$9.00
1g	98%	in stock	$26.00	$18.00
25g	98%	in stock	$394.00	$276.00

Description

• Catalog Number: AA65746
• Chemical Name: Azilsartan
• CAS Number: 147403-03-0
• Molecular Formula: C25H20N4O5
• Molecular Weight: 456.4501
• MDL Number: MFCD20278186
• SMILES: CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1[nH]oc(=O)n1)c(ccc2)C(=O)O

Computed Properties

• Complexity: 783
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• XLogP3: 4.4

Literature

• Azilsartan and its Zn(II) complex. Synthesis, anticancer mechanisms of action and binding to bovine serum albumin.

  Toxicology in vitro : an international journal published in association with BIBRA 20180401

• Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.

  Hypertension research : official journal of the Japanese Society of Hypertension 20140901

• Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension.

  Clinical therapeutics 20140501

• Assessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1.

  Chemosphere 20120601

• Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120501

• Differential pharmacology and benefit/risk of azilsartan compared to other sartans.

  Vascular health and risk management 20120101

• Critical evaluation of the efficacy and tolerability of azilsartan.

  Vascular health and risk management 20120101

• Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.

  Vascular health and risk management 20120101

• Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats.

  Diabetes, obesity & metabolism 20111201

• Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.

  Journal of clinical hypertension (Greenwich, Conn.) 20110701

• In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.

  The Journal of pharmacology and experimental therapeutics 20110301

• Azilsartan: a newly approved angiotensin II receptor blocker.

  Cardiology in review 20110101

• TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation.

  American journal of hypertension 20070501